

Xiang Zhang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/12097452/publications.pdf>

Version: 2024-02-01

21
papers

1,994
citations

430874

18
h-index

752698

20
g-index

21
all docs

21
docs citations

21
times ranked

3312
citing authors

#	ARTICLE	IF	CITATIONS
1	Dietary cholesterol drives fatty liver-associated liver cancer by modulating gut microbiota and metabolites. <i>Gut</i> , 2021, 70, 761-774.	12.1	382
2	<i>Peptostreptococcus anaerobius</i> Induces Intracellular Cholesterol Biosynthesis in Colon Cells to Induce Proliferation and Causes Dysplasia in Mice. <i>Gastroenterology</i> , 2017, 152, 1419-1433.e5.	1.3	308
3	Animal models of non-alcoholic fatty liver disease: current perspectives and recent advances. <i>Journal of Pathology</i> , 2017, 241, 36-44.	4.5	256
4	CXCL10 plays a key role as an inflammatory mediator and a non-invasive biomarker of non-alcoholic steatohepatitis. <i>Journal of Hepatology</i> , 2014, 61, 1365-1375.	3.7	178
5	Obesity, insulin resistance, NASH and hepatocellular carcinoma. <i>Seminars in Cancer Biology</i> , 2013, 23, 483-491.	9.6	128
6	CXC chemokine receptor 3 promotes steatohepatitis in mice through mediating inflammatory cytokines, macrophages and autophagy. <i>Journal of Hepatology</i> , 2016, 64, 160-170.	3.7	126
7	Macrophage p38 β promotes nutritional steatohepatitis through M1 polarization. <i>Journal of Hepatology</i> , 2019, 71, 163-174.	3.7	112
8	O-GlcNAc transferase promotes fatty liver-associated liver cancer through inducing palmitic acid and activating endoplasmic reticulum stress. <i>Journal of Hepatology</i> , 2017, 67, 310-320.	3.7	98
9	Defective lysosomal clearance of autophagosomes and its clinical implications in nonalcoholic steatohepatitis. <i>FASEB Journal</i> , 2018, 32, 37-51.	0.5	60
10	Pro-Inflammatory CXCR3 Impairs Mitochondrial Function in Experimental Non-Alcoholic Steatohepatitis. <i>Theranostics</i> , 2017, 7, 4192-4203.	10.0	49
11	The phytochemical polydatin ameliorates non-alcoholic steatohepatitis by restoring lysosomal function and autophagic flux. <i>Journal of Cellular and Molecular Medicine</i> , 2019, 23, 4290-4300.	3.6	49
12	The Role of Gut-Liver Axis in Gut Microbiome Dysbiosis Associated NAFLD and NAFLD-HCC. <i>Biomedicines</i> , 2022, 10, 524.	3.2	42
13	Bone marrow-derived macrophage contributes to fibrosing steatohepatitis through activating hepatic stellate cells. <i>Journal of Pathology</i> , 2019, 248, 488-500.	4.5	36
14	New insights and therapeutic implication of gut microbiota in non-alcoholic fatty liver disease and its associated liver cancer. <i>Cancer Letters</i> , 2019, 459, 186-191.	7.2	30
15	NAFLD Related-HCC: The Relationship with Metabolic Disorders. <i>Advances in Experimental Medicine and Biology</i> , 2018, 1061, 55-62.	1.6	29
16	C-X-C motif chemokine 10 in non-alcoholic steatohepatitis: role as a pro-inflammatory factor and clinical implication. <i>Expert Reviews in Molecular Medicine</i> , 2016, 18, e16.	3.9	28
17	C-X-C Motif Chemokine 10 Impairs Autophagy and Autolysosome Formation in Non-alcoholic Steatohepatitis. <i>Theranostics</i> , 2017, 7, 2822-2836.	10.0	27
18	Pathophysiological mechanisms and therapeutic potentials of macrophages in non-alcoholic steatohepatitis. <i>Expert Opinion on Therapeutic Targets</i> , 2016, 20, 615-626.	3.4	22

#	ARTICLE	IF	CITATIONS
19	Diet and gut microbiome in fatty liver and its associated liver cancer. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2022, 37, 7-14.	2.8	18
20	Animal Models of Non-alcoholic Fatty Liver Diseases and Its Associated Liver Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2018, 1061, 139-147.	1.6	10
21	Obesity and Cancer. , 2016, , 211-220.		6